NCT04309669View on ClinicalTrials.gov

Assessment of the eFficacy, the Onset-of-Action and the Safety of Tot'héma® in Adults With Moderate Iron Deficiency Anaemia

PHASE4CompletedINTERVENTIONAL

Enrollment

167

Participants

Timeline

Start Date

November 12, 2020

Primary Completion Date

October 6, 2023

Study Completion Date

October 6, 2023

Conditions

Anemia

Interventions

DRUG

TOT'HEMA

three ampoules per day during 12 weeks

Trial Locations (1)

75013

Hopital Pitié Salpétrière - Médecine Interne et Immunologie Clinique, Paris

All Listed Sponsors

lead

Laboratoire Innotech International

INDUSTRY

NCT04309669 - Assessment of the eFficacy, the Onset-of-Action and the Safety of Tot'héma® in Adults With Moderate Iron Deficiency Anaemia | Biotech Hunter | Biotech Hunter